Literature DB >> 7830324

Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL).

E Casiglia1, P Spolaore, A Mazza, G Ginocchio, G Colangeli, C Onesto, G Di Menza, L Pegoraro, G B Ambrosio.   

Abstract

Although limited numbers of elderly subjects have occasionally been included in population-based studies, only a few studies have been conducted specifically on elderly hypertensives, and practically none at a population level. We studied 655 hypertensive subjects from a cohort of 2,254 elderly subjects. The intervention consisted of the creation of a Hypertension Outpatients' Clinic under our auspices but with complete co-operation from general practitioners, randomizing the identified hypertensive patients into pre-established therapeutic drug regimens, and early follow-up recording of mortality for 7 years. The drugs used were clonidine (n = 61), nifedipine (n = 146) and the fixed combination of atenolol+chlorthalidone (n = 144); 304 subjects underwent "free therapy" by their personal physicians without any special intervention. There were 1,404 normotensive subjects. Overall 7-year follow-up mortality was 34.9% in the hypertensive subjects receiving "free therapy", 22.5% in those receiving "special care", and 24.2% in the normotensives. Cardiovascular mortality was respectively 23.7%, 12.2%, and 12.0%. Overall and cardiovascular annual cumulative mortality were significantly lower in the << special therapy >> than in the << free therapy >> group. The fixed combination of atenolol and chlorthalidone reduced mortality below that of the normotensives, independent of other cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7830324     DOI: 10.1536/ihj.35.589

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  18 in total

Review 1.  Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?

Authors:  J M Wright; C H Lee; G K Chambers
Journal:  CMAJ       Date:  1999-07-13       Impact factor: 8.262

2.  Health outcomes associated with calcium antagonists.

Authors:  R B Thakkar; S Oparil
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

3.  Calcium channel blockers: is the jury still out?

Authors:  J M Wright
Journal:  BMJ       Date:  1998-12-05

4.  Impaired glucose tolerance and its co-variates among 2079 non-diabetic elderly subjects. Ten-year mortality and morbidity in the CASTEL study. CArdiovascular STudy in the ELderly.

Authors:  E Casiglia; P Pauletto; A Mazza; G Ginocchio; G di Menza; L Pavan; P Tramontin; M Capuani; A C Pessina
Journal:  Acta Diabetol       Date:  1996-12       Impact factor: 4.280

5.  [Prevention of arteriosclerosis. Importance of the treatment of arterial hypertension].

Authors:  G Bönner; D B Gysan; G Sauer
Journal:  Z Kardiol       Date:  2005

Review 6.  [Blood pressure and the brain].

Authors:  A Hartmann; S Moskau
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

7.  Pulse pressure and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis.

Authors:  Ginger J Winston; Walter Palmas; Joao Lima; Joseph F Polak; Alain G Bertoni; Gregory Burke; John Eng; Rebecca Gottesman; Steven Shea
Journal:  Am J Hypertens       Date:  2013-02-06       Impact factor: 2.689

Review 8.  The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.

Authors:  Yogini Ratnasabapathy; Carlene M M Lawes; Craig S Anderson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 9.  Use of calcium channel antagonists for the treatment of hypertension in the elderly.

Authors:  Hans-Michael Steffen
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  Nifedipine gastrointestinal therapeutic system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.